1.0Heximahttps://hexima.com.aurich600338<blockquote class="wp-embedded-content"><a href="https://hexima.com.au/hexima-doses-first-patient-phase-1-2a-trial-hxp124-novel-topical-treatment-fungal-nail-infections/">Hexima doses first patient in phase 1/2a trial of HXP124</a></blockquote> <script type='text/javascript'> <!--//--><![CDATA[//><!-- /*! This file is auto-generated */ !function(c,d){"use strict";var e=!1,n=!1;if(d.querySelector)if(c.addEventListener)e=!0;if(c.wp=c.wp||{},!c.wp.receiveEmbedMessage)if(c.wp.receiveEmbedMessage=function(e){var t=e.data;if(t)if(t.secret||t.message||t.value)if(!/[^a-zA-Z0-9]/.test(t.secret)){for(var r,a,i,s=d.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),n=d.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),o=0;o<n.length;o++)n[o].style.display="none";for(o=0;o<s.length;o++)if(r=s[o],e.source===r.contentWindow){if(r.removeAttribute("style"),"height"===t.message){if(1e3<(i=parseInt(t.value,10)))i=1e3;else if(~~i<200)i=200;r.height=i}if("link"===t.message)if(a=d.createElement("a"),i=d.createElement("a"),a.href=r.getAttribute("src"),i.href=t.value,i.host===a.host)if(d.activeElement===r)c.top.location.href=t.value}}},e)c.addEventListener("message",c.wp.receiveEmbedMessage,!1),d.addEventListener("DOMContentLoaded",t,!1),c.addEventListener("load",t,!1);function t(){if(!n){n=!0;for(var e,t,r=-1!==navigator.appVersion.indexOf("MSIE 10"),a=!!navigator.userAgent.match(/Trident.*rv:11\./),i=d.querySelectorAll("iframe.wp-embedded-content"),s=0;s<i.length;s++){if(!(e=i[s]).getAttribute("data-secret"))t=Math.random().toString(36).substr(2,10),e.src+="#?secret="+t,e.setAttribute("data-secret",t);if(r||a)(t=e.cloneNode(!0)).removeAttribute("security"),e.parentNode.replaceChild(t,e)}}}}(window,document); //--><!]]> </script><iframe sandbox="allow-scripts" security="restricted" src="https://hexima.com.au/hexima-doses-first-patient-phase-1-2a-trial-hxp124-novel-topical-treatment-fungal-nail-infections/embed/" width="600" height="338" title="“Hexima doses first patient in phase 1/2a trial of HXP124” — Hexima" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe>https://hexima.com.au/wp-content/uploads/2014/06/Banners-news-100px.gif1024100Hexima Limited is pleased to announce today that the first patient has been dosed in its phase 1/2a clinical trial of HXP124 in patients with fungal nail infections. Hexima’s CEO Dr Nicole van der Weerden said “Advancing HXP124 into clinical testing has been a major focus for Hexima through 2017 and we are delighted to have achieved this key milestone. This study will provide important information about the safety of HXP124 and potentially the ability of HXP124 to treat fungal nail infections and is a critical step in the development of this novel topical drug.” Click on title to read more.